Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Billionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world’s most successful alternative ...

DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.

The geroscience hypothesis focuses on extending the healthy lifespan by targeting aging mechanisms. Recent advances in ...

New research suggests that commonly used medications like antibiotics, antivirals, and anti-inflammatories could lower the ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Research shows that GLP-1 receptor agonists like Ozempic can help you drop weight, manage diabetes, and even potentially ...

Alzheimer's disease is likely caused by stalled protein processing in the brain, according to a new study.

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.